article thumbnail

Polypharmacy Case Study – Sleepers, Diabetes, and More

Med Ed 101

In this polypharmacy case study, we review a medication list and try to identify areas to reduce medications and avoid adverse reactions. EK is a 66-year-old female with a past medical history of insomnia, diabetes, GERD, hypertension, hyperlipidemia, obesity, recurrent UTI, and osteoarthritis.

article thumbnail

MHRA urges pharmacists to be alert to signs of GLP-1 RA ‘misuse’

The Pharmacist

Healthcare professionals should also ensure patients are aware of the side-effects of the diabetes and weight loss injections and report any adverse reactions through the Yellow Card reporting scheme, the Medicines and Healthcare […] The post MHRA urges pharmacists to be alert to signs of GLP-1 RA ‘misuse’ appeared first on The Pharmacist.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

First cell therapy approved for Type 1 diabetes

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Lantidra, the first cell therapy for certain adults with Type 1 diabetes. In some Type 1 diabetes patients, these infused cells can produce enough insulin. Therefore the patient does not need to continue to take insulin by injections or pump to control blood sugar levels.

article thumbnail

FDA, Novo Nordisk Warn of Counterfeit Semaglutide Injection Pens

Pharmacy Times

A counterfeit medication was reportedly purchased at a retail pharmacy, appearing to have contained another type of diabetes medication that led to an adverse reaction.

article thumbnail

CellTrans’ Lantidra Receives the US FDA’s Approval for the Treatment of Type 1 Diabetes

PharmaShots

11 for 1-5yrs. & 10 for ≥5yrs. Your go-to media platform for customized news ranging for multiple indications.

article thumbnail

Novo launches type 2 diabetes pill in UK after NICE waives review

pharmaphorum

Novo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost-effectiveness watchdog NICE decided that there was no need to review it. The most common adverse reactions were nausea, diarrhoea and hypoglycemia when used with insulin and/or sulfonylurea.

article thumbnail

Regional variations uncovered in the impact of dexamethasone treatment for severe COVID-19: Study

Express Pharma

There were some significant variations between the two areas, though, such as India’s lower weight and its higher use of antivirals and other therapies; also the higher proportion of patients with Diabetes in India. Serious adverse reactions: Regarding serious adverse reactions (SARs), an interesting finding was made.